NCT04246567

Brief Summary

The aim of this study to evaluate the patients who underwent controlled hypotensive anesthesia under standardized depth of anesthesia with total intravenous anesthesia or inhalation anesthesia; preoperative and 30. ,60. ,120. second of intraoperative period blood HIF 1a, TAS, TOS measurement and to investigate tissue hypoxia secondary to hypotensive anesthesia and the changes of the mediators at the tissue level and which hypotensive anesthesia technique is related.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Trial recruitment is currently suspended
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 22, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 29, 2020

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2021

Completed
Last Updated

May 11, 2020

Status Verified

May 1, 2020

Enrollment Period

6 months

First QC Date

January 22, 2020

Last Update Submit

May 7, 2020

Conditions

Keywords

hypotensive anesthesiaHIF 1atotal intravenous anesthesiainhalation anesthesia

Outcome Measures

Primary Outcomes (3)

  • Evaluation of the relationship between hypotensive anesthesia technique and tissue hypoxia by HIF1a

    Under normoxic conditions, HIF 1a protein can hardly be detected, but when hypoxia starts, its expression starts within 2 minutes and peaks at 4-8 hours of hypoxia. 5 ml blood was taken into MiniCollect® tubes from the venous cannula placed before anesthesia (t0) induction for measure HIF 1a,TAS and TOS. 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation 5 ml of blood was taken again from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory. The collected blood was centrifuged at 2000 x g for 10 minutes and the separated sera were sent to the biochemical laboratory to be stored at -80 ° C until the study was performed.

    Change from Baseline HIF 1a 30th minute (t1), 1st hour (t2) and 2st hour (t3)

  • Evaluation of the relationship between hypotensive anesthesia technique and tissue hypoxia by the concentration of TAS

    Plasma TAS and TOS levels are measured with a commercial kit developed by Erel. Values for plasma TAS are expressed in millimeters by the Trolox value per liter. 5 ml blood was taken into MiniCollect® tubes from the venous cannula placed before anesthesia (t0) induction for measure HIF 1a,TAS and TOS. 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation 5 ml of blood was taken again from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory. The collected blood was centrifuged at 2000 x g for 10 minutes and the separated sera were sent to the biochemical laboratory to be stored at -80 ° C until the study was performed.

    Change from Baseline TAS levels at 30th minute (t1), 1st hour (t2) and 2st hour (t3)

  • Evaluation of the relationship between hypotensive anesthesia technique and tissue hypoxia by the concentration of TOS

    Measurement for TOS is calibrated with hydrogen peroxide and the results are expressed in micromolar by the hydrogen peroxide value per liter (mmol H2O2 equiv / L).5 ml blood was taken into MiniCollect® tubes from the venous cannula placed before anesthesia (t0) induction for measure HIF 1a,TAS and TOS. 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation 5 ml of blood was taken again from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory. The collected blood was centrifuged at 2000 x g for 10 minutes and the separated sera were sent to the biochemical laboratory to be stored at -80 ° C until the study was performed.

    Change from Baseline TOS levels at 30th minute (t1), 1st hour (t2) and 2st hour (t3)

Secondary Outcomes (4)

  • surgical satisfaction

    postoperative 1 minute

  • bleeding scores

    postoperative 1 minute

  • anesthetic consumption for group 1 propofol consumption (mg) and remifentanyl consumption(microgram)

    postoperative 1 minute

  • anesthetic consumption for group 2 N2O2 consumption (ml) and sevoflurane consumption (ml)

    postoperative 1 minute

Study Arms (2)

Total intravenous anesthesia technique for group 1 patients

ACTIVE COMPARATOR

Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 6-10 mg / kg / h propofol and 0.0,4mcg / kg remifentanyl infusion / min. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation. Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals. Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory

Procedure: Mean Blood Pressure (MBP)Drug: Add to 0.5 mcg / kg fentanyl.

Inhalation anesthesia technique for group 2 patients

ACTIVE COMPARATOR

Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 40% Oxygen 60% N2O2 and Sevoflurane at a concentration of 1.5-3.5% with 2 L / minTGA to provide a value of BIS between 40-60. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation. Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals. Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory

Procedure: Mean Blood Pressure (MBP)Drug: Add to 0.5 mcg / kg fentanyl.

Interventions

Mean blood pressure (MBP) for patients 50-65 mmHg

Inhalation anesthesia technique for group 2 patientsTotal intravenous anesthesia technique for group 1 patients

When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.

Inhalation anesthesia technique for group 2 patientsTotal intravenous anesthesia technique for group 1 patients

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • years old
  • ASA Physical Status Classification System 1
  • Undergoing to Elective rhinoplasty

You may not qualify if:

  • Patients have any autoimmune disease
  • Smoking of patients
  • Development of any allergic reaction during the procedure
  • Failure to collect blood to be examined at the appropriate time
  • Body mass index is less than 19 or greater than 30
  • Termination criteria
  • Development of severe hypotension and bradycardia during measurements
  • Development of severe drug allergy during follow-up
  • In the event of any complications related to the surgical procedure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bezmialem Vakif University

Istanbul, Fatih, 34093, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hypoxia

Interventions

Arterial PressureFentanyl

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Blood PressureHemodynamicsCardiovascular Physiological PhenomenaCirculatory and Respiratory Physiological PhenomenaPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Hayrettin Daşkaya, MD

    Bezmialem Vakif University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The investigators divided the patients to two groups. Patients were divided into two groups with a lottery. Surgeons did not know which hypotensive anesthesia technique were used. And surgeons evaluated surgical satisfaction and bleeding scores
Purpose
SCREENING
Intervention Model
PARALLEL
Model Details: A total of 60 ASA 1 patients aged between 18-55 who underwent elective rhinoplasty surgery were included the study.The patients were divided into two groups. One group received hypotensive anesthesia with total intravenous anesthesia technique according to MBP and the other group received hypotensive anesthesia with inhalation anesthesia technique. Blood samples were taken from all patients before anesthesia induction and 30. ,60. ,120. second of intraoperative period for TAS, TOS, HIF 1a. At the and of the operation patients were fallowed in the post anesthesia care unit for 30 minutes and pain and nause vomiting scores were evaluated. İn addition, surgical satisfaction and bleeding scores and anesthetic consumption of both groups were recorded
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2020

First Posted

January 29, 2020

Study Start

March 1, 2019

Primary Completion

September 1, 2019

Study Completion

January 1, 2021

Last Updated

May 11, 2020

Record last verified: 2020-05

Locations